Mind Medicine (MindMed) Inc.
MNMDMind Medicine (MindMed) Inc., doing business as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
MM120 (LSD D-Tartrate)
Generalized Anxiety Disorder
MM-120
ADHD
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Autism Spectrum Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MM120 (LSD D-Tartrate) | Phase 3 | Generalized Anxiety Disorder | - | - |
MM-120 | Phase 2 | ADHD | - | - |
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) | Phase 2 | Autism Spectrum Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Mind Medicine (MindMed) Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Mind Medicine (MindMed) Inc.'s (MNMD) pipeline across Phase 3, Phase 2. Its lead program is MM120 (LSD D-Tartrate) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mind Medicine (MindMed) Inc.'s next FDA catalyst?→
Mind Medicine (MindMed) Inc.'s (MNMD) next tracked catalyst is a Phase 3 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MNMD biotech catalysts?→
Add MNMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mind Medicine (MindMed) Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.